Bristol-Myers Squibb Stock News

We present a highly diversified yet simple portfolio of 10 positions, with 9 funds and one individual MLP stock. The portfolio has been designed for retirees and investors planning for retirement, with a 6% current income yield and potentially 6% plus dividend growth. The portfolio presented uses a hands-off approach, and it is diversified among many asset classes as well as different sectors o...

Is Bristol Myers Squibb Stock a Buy?

Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks

Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next fireside chat. And again, thanks, everyone, for your attendance.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $642 million in the third quarter of 2024, increasing by 10.9% year-on-year and 1.9% quarter-on-quarter. Moreover, on September 26, 2024, the company announced the long-awaited approval of Cobenfy for the...

Key Points Yields have drifted higher since the Federal Reserve cut rates in September.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite.